









All Databases

PubMed

Nucleotide

Preview/Index

Protein

Structure

OMIM

PMC Journals Go

Search PubMed

for

Clipboard History

Details

Clear

2137.086 Examiner copy reference

Display Abstract

Limits

· Show 20

Sort by

Send to

All: 1 Review: 0

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

About Entrez

Text Version

PubMed Services Journals Database MeSH Database Single Citation Matcher **Batch Citation Matcher** Clinical Queries **Special Queries** LinkOut My NCBI (Cubby)

Related Resources **Order Documents** NLM Catalog NLM Gateway TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central

1: Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11949-53. Related Articles, Links ਛੋੜੇ ਜੋ ਜੋ full text article FREE full text article at www.pnas.org in PubMed Central


Detection of glutamine synthetase in the cerebrospinal fluid of Alzheimer diseased patients: a potential diagnostic biochemical marker.

Gunnersen D, Haley B.

Department of Biochemistry, College of Pharmacy, University of Kentucky, Lexington 40536-0084.

In this report, 8- and 2-azidoadenosine 5'-[gamma-32P]triphosphate were used to examine cerebrospinal fluid (CSF) samples for the presence of an ATP binding protein unique to individuals with Alzheimer disease (AD). A 42-kDa ATP binding protein was found in the CSF of AD patients that is not observed in CSF from normal patients or other neurological controls. The photolabeling is saturated with 30 microM 2-azidoadenosine 5'-[gamma-32P]triphosphate. Photoinsertion can be totally prevented by the addition of 25 microM ATP. Photoinsertion of 2-azidoadenosine 5'triphosphate into the protein is only weakly protected by other nucleotides such as ADP and GTP, indicating that this is a specific ATP binding protein. A total of 83 CSF samples were examined in a blind manner. The 42-kDa protein was detected in 38 of 39 AD CSF samples and in only 1 of 44 control samples. This protein was identified as glutamine synthetase [GS; glutamate-ammonia ligase; L-glutamate:ammonia ligase (ADP-forming), EC 6.3.1.2] based on similar nucleotide binding properties, comigration on two-dimensional gels, reaction with a polyclonal anti-GS antibody, and the presence of significant GS enzyme activity in AD CSF. In brain, GS plays a key role in elimination of free ammonia and also converts the neurotransmitter and excitotoxic amino acid glutamate to glutamine, which is not neurotoxic. The involvement of GS, if any, in the onset of AD is unknown. However, the presence of GS in the CSF of terminal AD patients suggests that this enzyme may be a useful diagnostic marker and that further study is warranted to determine any possible role for glutamate metabolism in the pathology of AD.

PMID: 1361232 [PubMed - indexed for MEDLINE]



Display Abstract

Show 20 Sort by

Send to

Write to the Help Desk NCBI | NLM | NIH


Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Jun 6 2005 07:23:23









All Databases

PubMed

Limits

Nucleotide

Protein Genome

Structure

MIMO

PMC

Go

Bool

Search PubMed

for

Preview/Index

History

Clipboard

Details

9132.086

Display Abstract

Show 20

Sort by

Details

s 9102.006
Send to Examiner (opy

About Entrez

Text Version

All: 1 Review: 0 🔀

reference# 5

Journals

Clear

Entrez PubMed Overview

Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI (Cubby)

Related Resources Order Documents NLM Catalog NLM Gateway TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central ☐ 1: Brain Res. 1995 Mar 27;675(1-2):75-82.

Related Articles, Links

Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease.

Walker DG, Yasuhara O, Patston PA, McGeer EG, McGeer PL.

Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, Canada.

C1 inhibitor was identified in human brain tissue by Western blotting and by immunohistochemistry using multiple antibodies to the native protein. The presence of C1 inhibitor mRNA was identified by reverse transcriptase-polymerase chain reaction analysis of brain mRNA extracts. The mRNA was also detected in cultured postmortem human microglia and in the IMR-32 human neuroblastoma cell line. Immunohistochemically, the native protein was detected in residual serum of capillaries and pyramidal neurons of both control and Alzheimer disease cases, as well as in occasional senile plaques of Alzheimer tissue. The reacted protein was detected on dystrophic neurites and neuropil threads in Alzheimer tissue by 4C3 monoclonal antibody, which recognizes a neoepitope following suicide inhibition. These data indicate that C1 inhibitor, a regulatory molecule controlling multiple inflammatory proteolytic cascades, is produced in normal brain. In Alzheimer disease, C1 inhibitor undergoes a prominent reaction in abnormal neuronal processes, such as dystrophic neurites and neuropil threads.

PMID: 7796155 [PubMed - indexed for MEDLINE]

Display Abstract

Show 20

Sort by

Send to

Write to the Help Desk
NCB! | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Jun 6 2005 07:23:23









All Databases

PubMed

Limits

Nucleotide

Protein

Genome

Structure

OMIM

PMC Go Bool

Search PubMed

for

Preview/Index

Clipboard History

Details

Display Abstract

Show 20

Sort by

Send to

About Entrez

Text Version

Tutorial

E-Utilities

Entrez PubMed Overview Help | FAQ

New/Noteworthy

PubMed Services

Batch Citation Matcher

Journals Database MeSH Database Single Citation Matcher

Clinical Queries **Special Queries** LinkOut

My NCBI (Cubby)

Order Documents

Consumer Health

PubMed Central

NLM Catalog NLM Gateway

Clinical Alerts ClinicalTrials.gov

TOXNET

Related Resources

All: 1 Review: 0 reference # 6

Journals

Clear

Related Articles, Links

☐ 1: Am J Pathol. 1999 Mar;154(3):927-36.

> Up-regulated production and activation of the complement system in Alzheimer's disease brain.

Yasojima K, Schwab C, McGeer EG, McGeer PL.

Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada.

We used reverse transcriptase-polymerase chain reaction and Western blotting techniques to measure the levels of complement mRNAs and their protein products in Alzheimer's disease (AD) brain compared with non-AD brain. mRNAs for C1q, C1r, C1s, C2, C3, C4, C5, C6, C7, C8, and C9 were detected in the 11 regions of brain that were investigated. The mRNA levels were markedly up-regulated in affected areas of AD brain. In the entorhinal cortex, hippocampus, and midtemporal gyrus, which had dense accumulations of plaques and tangles, C1q mRNA was increased 11- to 80fold over control levels, and C9 mRNA 10- to 27-fold. These levels were substantially higher than in the livers of the same cases. Western blot analysis of AD hippocampus established the presence of all of the native complement proteins as well as their activation products C4d, C3d, and the membrane attack complex. These data indicate that high levels of complement are being produced in affected areas of AD brain, that full activation of the classical complement pathway is continuously taking place, and that this activation may be contributing significantly to AD pathology.

PMID: 10079271 [PubMed - indexed for MEDLINE]

Display Abstract

Show 20

Sort by

Send to

Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Privacy Statement | Freedom of Information Act | Disclaimer

Jun 6 2005 07:23:23